Alnylam Soars as Drugmakers Circle Rival Biotechnology Company

Alnylam Pharmaceuticals Inc. rose as much as 12 percent, the most in more than a year, after Sanofi, which owns a stake in the company, accelerated its pursuit of another drugmaker as potential rivals circled, suggesting demand for biotechnology acquisitions may be picking up.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.